Protherics PLC announces Total Voting Rights

CHESHIRE, UK , the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following: Protherics' issued share capital consists of 340,417,123 ordinary shares with a nominal value of 2 pence each, with voting rights. Protherics does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Protherics is 340,417,123. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Protherics under the Financial Services Authority's Disclosure and Transparency Rules. / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs [phone] Julie Vickers, Company Secretary [phone] Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott [phone] New York: John Capodanno, Jonathan Birt [phone] Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com